Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Pharmaceutical Companies Performance Tables' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Pharmaceutical Companies Performance Tables 2005 |
November 2006 | £295 | 100 % |
|
EvaluatePharma® Yearbook Company Performance Tables |
August 2008 | £1450 | 50 % |
|
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery Equipment, Technologies and Companies, 2006-2011 |
January 2007 | £1460 | 39 % |
|
Scrip's Pharmaceutical Company League Tables 2007 |
January 2007 | £1870 | 35 % |
|
2007 The Worldwide Biochip & Equipment Market |
August 2006 | £835 | 33.5 % |
|
PharmaVitae: Company Comparator Tool |
January 2009 | £24060 | 33 % |
|
Par Pharmaceutical Companies, Inc. - Financial and Strategic Analysis Review |
June 2009 | £80 | 31.15 % |
|
Ono Pharmaceutical Co Deals Partneringdesk briefing |
July 2005 | £215 | 30.5 % |
|
Otsuka Pharmaceutical Co Deals Partneringdesk briefing |
July 2005 | £215 | 30 % |
|
Pharmaceuticals in India |
March 2009 | £132 | 29.75 % |
|
Fujisawa Pharmaceutical Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 | 29.5 % |
|
Transdermal Drug Delivery Technologies, Markets and Companies |
February 2010 | £1780 | 29.5 % |
|
Wound Treatment in China |
December 2005 | £450 | 29.4 % |
|
Par Pharmaceutical Companies Inc -Financial Company Report |
February 2008 | £110 | 29 % |
|
Takeda Pharmaceutical Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 | 29 % |
|
Yamanouchi Pharmaceutical Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 | 29 % |
|
Uzbekistan Pharmaceuticals and Healthcare Report Q1 2010 |
November 2009 | £250 | 28.7 % |
|
Daiichi Pharmaceutical Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 | 28.5 % |
|
Leading Pharmaceutical Companies Comparative Analysis |
September 2009 | £285 | 28 % |
|
Generics in Canada |
August 2007 | £125 | 28 % |
|
Moldova Pharmaceuticals and Healthcare Report Q1 2010 |
November 2009 | £250 | 28 % |
|
Generics in France |
August 2007 | £125 | 28 % |
|
Generics in the Netherlands |
August 2007 | £125 | 27.65 % |
|
OTC Pharmaceuticals in South Korea |
February 2009 | £132 | 27.65 % |
|
Generics in Europe |
August 2007 | £125 | 27.65 % |
|
Morocco Pharmaceuticals and Healthcare Report Q4 2008 |
November 2008 | £250 | 27.65 % |
|
Global Generics |
August 2007 | £125 | 27.65 % |
|
Teva Pharmaceutical Industries Ltd Deals Partneringdesk briefing |
July 2005 | £215 | 27.5 % |
|
Global Biotechnology Industry 2006 |
June 2006 | £550 | 27.3 % |
|
Generics in Belgium |
August 2007 | £125 | 27.3 % |
|
OTC Pharmaceuticals in India |
February 2009 | £132 | 26.95 % |
|
Cough, Cold and Allergy (Hayfever) Remedies in China |
December 2005 | £450 | 26.95 % |
|
Algeria Pharmaceuticals and Healthcare Report Q4 2008 |
November 2008 | £250 | 26.6 % |
|
China Pharmaceuticals and Healthcare Report Q4 2008 |
November 2008 | £250 | 26.6 % |
|
NRT Smoking Cessation Aids in Japan |
June 2006 | £450 | 26.6 % |
|
Generics in China |
August 2007 | £125 | 26.6 % |
|
Pharmaceuticals in Belgium |
March 2009 | £132 | 26.6 % |
|
How to Forecast Generic Pharmaceutical Prices A practical methodology to calculate future generic product prices |
March 2009 | £2500 | 26.5 % |
|
Mergers and Acquisitions in the Pharmaceuticals Sector, 2009 Critical success factors for competing in a consolidating market |
April 2009 | £1955 | 26.25 % |
|
Pharmaceuticals in Europe |
March 2009 | £132 | 26.25 % |
|
Pharmaceuticals in South Korea |
March 2009 | £132 | 26.25 % |
|
Mergers and Aquisitions in the Pharmaceuticals Sector, 2009 Critical success factors for competing in a consolidating market |
April 2009 | £995 | 26.25 % |
|
Generics in Italy |
August 2007 | £125 | 26.25 % |
|
Moldova Pharmaceuticals and Healthcare Report Q1 2009 |
February 2009 | £250 | 26.25 % |
|
Catalyst Pharmaceutical Partners Inc. -Financial Company Report |
February 2008 | £110 | 26 % |
|
La Jolla Pharmaceutical Co -Financial Company Report |
February 2008 | £110 | 26 % |
|
Caraco Pharmaceutical Laboratories Ltd -Financial Company Report |
February 2008 | £110 | 26 % |
|
Medicis Pharmaceutical Corp -Financial Company Report |
February 2008 | £110 | 26 % |
|
IMCOR Pharmaceutical Co. -Financial Company Report |
February 2008 | £110 | 26 % |
|
Nastech Pharmaceutical Co Inc -Financial Company Report |
February 2008 | £110 | 26 % |
|
BioMarin Pharmaceutical Inc -Financial Company Report |
February 2008 | £110 | 26 % |
|
Benda Pharmaceutical, Inc -Financial Company Report |
February 2008 | £110 | 26 % |
|
Global Tuberculosis Strategies |
June 2007 | £2545 | 26 % |
|
Bactolac Pharmaceutical Inc. -Financial Company Report |
February 2008 | £110 | 26 % |
|
KV Pharmaceutical Co. -Financial Company Report |
February 2008 | £110 | 26 % |
|
LAM Pharmaceutical Corp -Financial Company Report |
February 2008 | £110 | 26 % |
|
Nymox Pharmaceutical Corporation -Financial Company Report |
February 2008 | £110 | 26 % |
|
Pharmaceutical Product Development Inc -Financial Company Report |
February 2008 | £110 | 26 % |
|
Huifeng Bio -Pharmaceutical Technology, Inc. -Financial Company Report |
February 2008 | £110 | 26 % |
|
Alliance Pharmaceutical Corporation -Financial Company Report |
February 2008 | £110 | 26 % |
|
Dov Pharmaceutical Inc -Financial Company Report |
February 2008 | £110 | 26 % |
|
Chugai Pharmaceutical Co Ltd -Financial Company Report |
February 2008 | £110 | 26 % |
|
Dragon Pharmaceutical Inc -Financial Company Report |
February 2008 | £110 | 26 % |
|
Teva Pharmaceutical Industries Ltd -Financial Company Report |
February 2008 | £110 | 26 % |
|
Simcere Pharmaceutical Group. -Financial Company Report |
February 2008 | £110 | 26 % |
|
Taro Pharmaceutical Industries Ltd -Financial Company Report |
February 2008 | £110 | 26 % |
|
Skystar Bio -Pharmaceutical Company Co., Ltd. -Financial Company Report |
February 2008 | £110 | 26 % |
|
The Indian Pharmaceutical Market to 2011 Competitive dynamics and major players |
July 2007 | £1495 | 25.9 % |
|
Romania Pharmaceuticals and Healthcare Report Q3 2007 |
February 2009 | £250 | 25.55 % |
|
Pharmaceuticals in Japan |
March 2009 | £132 | 25.55 % |
|
Watson Pharmaceuticals Inc Deals Partneringdesk briefing |
July 2005 | £215 | 25.5 % |
|
Drug Delivery in Japan |
October 2006 | £105 | 25.2 % |
|
Lebanon Pharmaceuticals and Healthcare Report Q4 2008 |
November 2008 | £250 | 25.2 % |
|
OTC Pharmaceuticals in China |
February 2009 | £132 | 25.2 % |
|
The Pharmaceutical Industry Key events and trends shaping its current status and future direction |
March 2006 | £3690 | 25.2 % |
|
Global Bulk Drugs Industry Report |
August 2006 | £550 | 25 % |
|
OTC Pharmaceuticals in Asia-Pacific |
February 2009 | £132 | 24.85 % |
|
Outlook 2007 |
January 2006 | £895 | 24.85 % |
|
United Arab Emirates Pharmaceuticals and Healthcare Report Q4 2008 |
November 2008 | £250 | 24.85 % |
|
Argentina Pharmaceuticals and Healthcare Report Q3 2008 |
July 2008 | £425 | 24.85 % |
|
GlaxoSmithKline plc: PharmaVitae Profile |
October 2010 | £5700 | 24.5 % |
|
Peru Pharmaceuticals and Healthcare Report Q4 2008 |
November 2008 | £250 | 24.5 % |
|
Serbia Pharmaceuticals and Healthcare Report Q4 2008 |
November 2008 | £250 | 24.5 % |
|
Altana Pharmaceutical Company Intelligence Report |
August 2006 | £795 | 24.5 % |
|
Key Players in Pharmaceutical Contract Manufacturing Market developments, outsourcing hotspots and growth strategies |
March 2009 | £2025 | 24.5 % |
|
Global Pharmaceuticals - Yearly Update 2006 |
July 2007 | £600 | 24.5 % |
|
Computer Systems Validation Quality Assurance, Risk Management, and Regulatory Compliance for Pharmaceutical and Healthcare Companies |
December 2003 | £299 | 24.5 % |
|
Czech Republic Pharmaceuticals and Healthcare Report Q1 2009 |
February 2009 | £250 | 24.15 % |
|
Specialty Pharma Market Outlook, The Key players, new company growth models and emerging opportunities |
October 2006 | £1495 | 24.15 % |
|
Zimbabwe Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 24.15 % |
|
Greece Pharmaceuticals and Healthcare Report Q4 2008 |
November 2008 | £250 | 24.15 % |
|
Mergers, acquisitions and licensing to continue drive industry growth |
October 2006 | £895 | 24.15 % |
|
Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems |
September 2009 | £1905 | 24.15 % |
|
Nitric Oxide Therapeutics, Markets and Companies |
February 2010 | £1780 | 24 % |
|
Bioarrays for Life Science Research, Diagnostics and Drug R&D |
August 2009 | £1590 | 24 % |
|
Global Hepatitis Strategies |
August 2007 | £2545 | 24 % |
|
Pharmaceutical Regulatory Affairs in The Eu & US |
January 2006 | £1095 | 24 % |
|
Baxter International Inc Deals Partneringdesk briefing |
July 2005 | £215 | 24 % |
|
China Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 23.8 % |
|
Drug Delivery in Asia-Pacific |
October 2006 | £105 | 23.8 % |
|
France Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 23.8 % |
|
Health Care Equipment & Supplies in China |
July 2008 | £180 | 23.8 % |
|
OTC Pharmaceuticals in Taiwan |
February 2009 | £132 | 23.8 % |
|
Menarini: PharmaVitae Profile |
March 2009 | £3010 | 23.8 % |
|
Bahrain Pharmaceuticals and Healthcare Report Q2 2009 |
May 2009 | £250 | 23.8 % |
|
From Idea to Market: Product Lifecycle Management in the Pharmaceutical Industry (Market Focus) |
July 2007 | £1000 | 23.8 % |
|
Iran Pharmaceuticals and Healthcare Report Q1 2010 |
November 2009 | £250 | 23.8 % |
|
H Lundbeck Deals Partneringdesk briefing |
July 2005 | £215 | 23.5 % |
|
Abbott Laboratories Deals Partneringdesk briefing |
July 2005 | £215 | 23.5 % |
|
Shire Pharmaceuticals Group PLC Deals Partneringdesk briefing |
July 2005 | £215 | 23.5 % |
|
Eye Care in India |
February 2008 | £450 | 23.45 % |
|
NRT Smoking Cessation Aids in India |
February 2008 | £450 | 23.45 % |
|
Netherlands Pharmaceuticals and Healthcare Report Q4 2008 |
October 2008 | £425 | 23.45 % |
|
United States Pharmaceuticals and Healthcare Report Q4 2008 |
November 2008 | £250 | 23.45 % |
|
Major Pharmaceutical Markets of the Middle East An overview of Egypt, Israel, Jordan, Lebanon, Saudi Arabia & UAE (2nd Ed) |
February 2009 | £1295 | 23.45 % |
|
United Arab Emirates Pharmaceuticals and Healthcare Report Q2 2009 |
April 2009 | £250 | 23.45 % |
|
Evaluation of Current Service Capabilities of Chinese Pharmaceutical Outsourcing Service Industry |
May 2008 | £560 | 23.1 % |
|
Saudi Arabia Pharmaceuticals and Healthcare Report Q3 2008 |
July 2008 | £425 | 23.1 % |
|
Vitamins and Dietary Supplements in India |
August 2006 | £450 | 23.1 % |
|
Hong Kong Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 23.1 % |
|
Bahrain Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 23.1 % |
|
Wound Treatments in India |
August 2006 | £450 | 23.1 % |
|
Global Biotechnology -Yearly Update 2006 |
July 2007 | £600 | 23.1 % |
|
Analgesics in India |
August 2006 | £450 | 23.1 % |
|
The Turkish Pharmaceutical Market Outlook to 2014 Policy environment, market structure, competitive landscape, growth opportunities |
January 2010 | £3835 | 23.1 % |
|
Peru Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 23.1 % |
|
Global Pharmaceutical Market Forecast to 2012 |
October 2008 | £1145 | 23.1 % |
|
Ion Channel Drug Discovery Therapeutic Opportunities & Technology Progress |
May 2004 | £870 | 23.1 % |
|
Molecular Diagnostics Technologies, Markets and Companies |
February 2010 | £3185 | 23 % |
|
Biogen Idec Deals Partneringdesk briefing |
July 2005 | £215 | 23 % |
|
Serono SA Deals Partneringdesk briefing |
July 2005 | £215 | 23 % |
|
The Top 100 Drug Delivery Companies Worldwide |
January 2004 | £555 | 23 % |
|
Purdue Pharma LP Deals Partneringdesk briefing |
July 2005 | £215 | 23 % |
|
Health and Wellness Healthcare Products in South Korea |
November 2006 | £650 | 22.75 % |
|
Pakistan Pharmaceuticals and Healthcare Report Q1 2009 |
January 2009 | £250 | 22.75 % |
|
Kazakhstan Pharmaceuticals and Healthcare Report Q2 2009 |
May 2009 | £250 | 22.75 % |
|
Generic Drug Market in Canada |
August 2009 | £765 | 22.75 % |
|
Russian Pharma Sector Analysis (2007) |
August 2007 | £700 | 22.75 % |
|
Mitsubishi Pharma Corporation Deals Partneringdesk briefing |
July 2005 | £215 | 22.5 % |
|
United Arab Emirates Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 22.4 % |
|
Pakistan Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 22.4 % |
|
Greece Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 22.4 % |
|
Mexico Pharmaceuticals and Healthcare Report Q3 2008 |
July 2008 | £425 | 22.4 % |
|
Wound Treatments in Brazil |
August 2007 | £450 | 22.4 % |
|
Pharmaceutical Market Trends, 2008 - 2012 Key market forecasts and growth opportunities (3rd Edition) |
November 2008 | £1350 | 22.4 % |
|
Czech Republic Pharmaceuticals and Healthcare Report Q3 2008 |
July 2008 | £425 | 22.4 % |
|
Medicated Skin Care in India |
February 2008 | £450 | 22.4 % |
|
Chile Pharmaceuticals and Healthcare Report Q2 2009 |
April 2009 | £250 | 22.4 % |
|
Global Life Sciences Tools & Services |
March 2007 | £110 | 22.4 % |
|
Thailand Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 22.05 % |
|
Serbia Pharmaceuticals and Healthcare Report Q1 2009 |
January 2009 | £250 | 22.05 % |
|
Taiwan Pharmaceuticals and Healthcare Report Q3 2007 |
February 2009 | £250 | 22.05 % |
|
Cough, Cold and Allergy (Hay Fever) Remedies in India |
February 2008 | £450 | 22.05 % |
|
Boehringer Ingelheim GmbH Deals Partneringdesk briefing |
July 2005 | £215 | 22 % |
|
Johnson & Johnson Deals Partneringdesk briefing |
July 2005 | £215 | 22 % |
|
Merck & Co Inc Deals Partneringdesk briefing |
July 2005 | £215 | 22 % |
|
Eye Care in Egypt |
September 2008 | £560 | 21.7 % |
|
Lebanon Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 21.7 % |
|
Animal Pharm's Top 20 2006 edition |
January 2006 | £795 | 21.7 % |
|
RFID in Pharmaceutical Manufacturing Cost Saving Strategies for Pharmaceutical Companies and Opportunities for Technology Companies |
March 2008 | £1270 | 21.7 % |
|
South Korea Pharmaceuticals and Healthcare Report Q3 2007 |
May 2009 | £250 | 21.7 % |
|
Analgesics in Egypt |
September 2008 | £560 | 21.7 % |
|
Drug Targets for Breast Cancer |
January 2006 | £1095 | 21.5 % |
|
GE Healthcare Medical Device Company Intelligence Report |
April 2009 | £495 | 21.5 % |
|
Vitamins And Dietary Supplements in Egypt |
September 2008 | £560 | 21.35 % |
|
Wound Treatments in Egypt |
September 2008 | £560 | 21.35 % |
|
Taiwan Pharmaceuticals and Healthcare Report Q2 2009 |
April 2009 | £250 | 21.35 % |
|
The True State of the Pharmaceutical Industry |
December 2008 | £495 | 21.35 % |
|
Slovenia Pharmaceuticals and Healthcare Report Q4 2008 |
October 2008 | £425 | 21.35 % |
|
Digestive Remedies in Egypt |
September 2008 | £560 | 21.35 % |
|
Indian Generics, 2008-2012 A Growing Threat to Westernised Markets |
January 2008 | £1600 | 21.35 % |
|
Animal Pharm's Top Tier Companies 2007 edition |
January 2007 | £895 | 21.35 % |
|
UCB Pharma Deals Partneringdesk briefing |
July 2005 | £215 | 21 % |
|
Pharmaceutical Distribution in Europe The Emergence of Direct-to-Pharmacy Supply |
February 2008 | £995 | 21 % |
|
Malaysia Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 21 % |
|
Nigeria Pharmaceuticals and Healthcare Report Q4 2008 |
November 2008 | £250 | 21 % |
|
Iran Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 21 % |
|
Medicated Skin Care in Egypt |
September 2008 | £560 | 21 % |
|
Indian Bioinformatics Industry |
April 2004 | £550 | 20.65 % |
|
The Future of the Pharmaceutical Packaging Industry Emerging Economies Poised to Capitalize on Increasing Demand |
December 2009 | £2230 | 20.65 % |
|
The Scandinavian Pharmaceutical Market Outlook to 2013 Policy environment, market structure, pipeline analysis, growth opportunities |
March 2009 | £2025 | 20.65 % |
|
Indian Bulk Drug Industry Insight 2007 |
May 2007 | £400 | 20.65 % |
|
Brazil Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 20.65 % |
|
Tanabe Seiyaku Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 | 20.5 % |
|
Alcon Inc Deals Partneringdesk briefing |
July 2005 | £215 | 20.5 % |
|
Vaccines The World Market |
February 2007 | £2545 | 20.5 % |
|
Sankyo Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 | 20.5 % |
|
Shionogi & Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 | 20.5 % |
|
Amgen Inc Deals Partneringdesk briefing |
July 2005 | £215 | 20.5 % |
|
Gilead Sciences Inc Deals Partneringdesk briefing |
July 2005 | £215 | 20.5 % |
|
Pharmaceuticals in China |
February 2006 | £3055 | 20.5 % |
|
AstraZeneca Deals Partneringdesk briefing |
July 2005 | £215 | 20.5 % |
|
Novo Nordisk A/S Deals Partneringdesk briefing |
July 2005 | £215 | 20.5 % |
|
Allergan Inc Deals Partneringdesk briefing |
July 2005 | £215 | 20.5 % |
|
Forest Laboratories Inc Deals Partneringdesk briefing |
July 2005 | £215 | 20.5 % |
|
Vaccines: The World Market |
February 2007 | £2545 | 20.5 % |
|
Effective Licensing & Commercialisation of Drug Delivery Systems 2006 |
July 2006 | £2500 | 20.3 % |
|
Cough, Cold and Allergy (hay Fever) Remedies in Egypt |
September 2008 | £560 | 20.3 % |
|
Hungary Pharmaceuticals and Healthcare Report Q3 2008 |
September 2008 | £425 | 20.3 % |
|
Guide to Pharmaceutical Outsourcing in China |
February 2008 | £625 | 20.3 % |
|
Barr Pharmaceuticals Inc Deals Partneringdesk briefing |
July 2005 | £215 | 20 % |
|
Eisai Co Ltd Deals Partneringdesk briefing |
July 2005 | £215 | 20 % |
|
Bayer AG Deals Partneringdesk briefing |
July 2005 | £215 | 20 % |
|
Eli Lilly and Company Deals Partneringdesk briefing |
July 2005 | £215 | 20 % |
|
Schering AG Deals Partneringdesk briefing |
July 2005 | £215 | 20 % |
|
Bulgaria Pharmaceuticals & Healthcare |
December 2006 | £395 | 19.95 % |
|
Consolidation in the Generic Pharmaceutical Industry An evolving landscape |
October 2007 | £1250 | 19.95 % |
|
KYOWA HAKKO KOGYO Co., Ltd. Strategic Analysis Profile |
February 2008 | £500 | 19.95 % |
|
Shire IMS Company Profile |
June 2006 | £249 | 19.6 % |
|
China Diabetes Drug Market Report The Chinese Hospital Cancer Drug Utilization |
January 2009 | £5090 | 19.6 % |
|
Allergan IMS Company Profile |
September 2006 | £3000 | 19.6 % |
|
Forest IMS Company Profile |
September 2006 | £249 | 19.6 % |
|
Actavis IMS Company Profile |
September 2006 | £249 | 19.6 % |
|
GlaxoSmithKline IMS Company Profile |
September 2006 | £249 | 19.6 % |
|
Japanese Pharmaceutical Market, 2006-2011 |
January 2006 | £1499 | 19.6 % |
|
Otsuka IMS Company Profile |
June 2006 | £249 | 19.6 % |
|
Stada IMS Company Profile |
September 2006 | £249 | 19.6 % |
|
Ono IMS Company Profile |
September 2006 | £249 | 19.6 % |
|
SkyePharma IMS Company Profile |
September 2006 | £249 | 19.6 % |
|
Astellas IMS Company Profile |
December 2006 | £249 | 19.6 % |
|
Taisho IMS Company Profile |
May 2006 | £249 | 19.6 % |
|
Mitsubishi Pharma IMS Company Profile |
September 2006 | £249 | 19.6 % |
|
Vaccines |
March 2008 | £600 | 19.6 % |
|
Drug Development Opportunities In China Regulation, Key Players And Initiatives For Domestic And International Markets |
September 2007 | £1495 | 19.6 % |
|
Pharmaceutical Contract Manufacturing Global Market Trends |
November 2009 | £1905 | 19.6 % |
|
World Market for Biosimilars and the Potential for US Follow-on Biologics, The |
August 2009 | £2355 | 19.6 % |
|
Merck KGaA IMS Company Profile |
September 2006 | £249 | 19.6 % |
|
India Pharmaceuticals and Healthcare Report Q3 2008 |
July 2008 | £425 | 19.5 % |
|
Schering-Plough Corporation Deals Partneringdesk briefing |
July 2005 | £215 | 19.5 % |
|
Global Diabetes Market; The Therapeutics, Diagnostics and Complications |
August 2006 | £1590 | 19.5 % |
|
Mylan Laboratories Inc Deals Partneringdesk briefing |
July 2005 | £215 | 19.5 % |
|
Merck KGaA Deals Partneringdesk briefing |
July 2005 | £215 | 19.5 % |
|
Altana AG Deals Partneringdesk briefing |
July 2005 | £215 | 19.5 % |
|
IVAX Corporation Deals Partneringdesk briefing |
July 2005 | £215 | 19.5 % |
|
Sanofi-Aventis Deals Partneringdesk briefing |
July 2005 | £215 | 19.5 % |
|
Bristol-Myers Squibb Company Deals Partneringdesk briefing |
July 2005 | £215 | 19.5 % |
|
Zentiva Company Profile |
January 2007 | £249 | 19.25 % |
|
Allergan IMS Company Profile |
June 2008 | £510 | 19.25 % |
|
Baxter IMS Company Profile |
May 2007 | £249 | 19.25 % |
|
Schering AG IMS Company Profile |
November 2006 | £249 | 19.25 % |
|
CNS Market Trends, 2007 to 2010 Key Market Forecasts and Growth Opportunities |
June 2007 | £995 | 19.25 % |
|
3M IMS Company Profile |
December 2006 | £249 | 19.25 % |
|
Endo Pharmaceuticals IMS Company Profile |
January 2007 | £249 | 19.25 % |
|
Dr Reddy's IMS Company Profile |
January 2007 | £249 | 19.25 % |
|
Philippines Pharmaceuticals Report Q1 2007 |
April 2007 | £395 | 19.25 % |
|
Pfizer IMS Company Profile |
July 2009 | £510 | 19.25 % |
|
Novartis IMS Company Profile |
December 2008 | £510 | 19.25 % |
|
Human Genome Sciences IMS Company Profile |
November 2008 | £510 | 19.25 % |
|
ratiopharm IMS Company Profile |
January 2007 | £249 | 19.25 % |
|
Genzyme IMS Company Profile |
December 2008 | £510 | 19.25 % |
|
Kyowa Hakko IMS Company Profile |
November 2006 | £249 | 19.25 % |
|
Millennium IMS Company Profile |
January 2007 | £510 | 19.25 % |
|
MundiPharma IMS Company Profile |
November 2008 | £510 | 19.25 % |
|
Meji Seika IMS Company Profile |
November 2006 | £249 | 19.25 % |
|
Lundbeck IMS Company Profile |
November 2008 | £510 | 19.25 % |
|
Fresenius IMS Company Profile |
October 2008 | £510 | 19.25 % |
|
Dr Reddy's IMS Company Profile |
January 2007 | £249 | 19.25 % |
|
AstraZeneca IMS Company Profile |
April 2009 | £510 | 19.25 % |
|
Pierre Fabre IMS Company Profile |
June 2008 | £510 | 19.25 % |
|
Sigma-Tau IMS Company Profile |
October 2008 | £510 | 19.25 % |
|
Acambis IMS Company Profile |
December 2006 | £510 | 19.25 % |
|
Par IMS Company Profile |
December 2006 | £249 | 19.25 % |
|
Nycomed IMS Company Profile |
July 2009 | £510 | 19.25 % |
|
Eisai IMS Company Profile |
December 2006 | £249 | 19.25 % |
|
Kowa IMS Company Profile |
December 2006 | £510 | 19.25 % |
|
Lilly IMS Company Profile |
July 2009 | £510 | 19.25 % |
|
Takeda IMS Company Profile |
June 2008 | £510 | 19.25 % |
|
Recordati IMS Company Profile |
June 2008 | £510 | 19.25 % |
|
Wyeth IMS Company Profile |
February 2009 | £510 | 19.25 % |
|
Watson IMS Company Profile |
November 2008 | £510 | 19.25 % |
|
Dr Reddy's IMS Company Profile |
January 2007 | £249 | 19.25 % |
|
UCB IMS Company Profile |
May 2008 | £510 | 19.25 % |
|
Genentech IMS Company Profile |
April 2009 | £510 | 19.25 % |
|
Menarini IMS Company Profile |
February 2007 | £249 | 19.25 % |
|
Abbott IMS Company Profile |
July 2009 | £510 | 19.25 % |
|
Elan IMS Company Profile |
April 2009 | £510 | 19.25 % |
|
Bausch & Lomb IMS Company Profile |
December 2006 | £249 | 19.25 % |
|
The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023 |
June 2008 | £1499 | 19.25 % |
|
China Allergy Drug Market Report The Chinese Allergy Cancer Drug Utilization |
March 2009 | £2865 | 19.25 % |
|
Shire |
July 2008 | £510 | 19.25 % |
|
Sepracor |
July 2008 | £510 | 19.25 % |
|
Chiesi IMS Company Profile |
August 2008 | £510 | 19.25 % |
|
Ipsen IMS Company Profile |
July 2009 | £510 | 19.25 % |
|
Zentiva IMS Company Profile |
October 2008 | £510 | 19.25 % |
|
Par Pharmaceutical IMS Company Profile |
October 2008 | £510 | 19.25 % |
|
Ferring IMS Company Profile |
December 2008 | £510 | 19.25 % |
|
Partneringreview 2006 – Industry Sector Volume 6 |
February 2006 | £1395 | 19.25 % |
|
Menarini |
July 2008 | £510 | 19.25 % |
|
Daiichi Sankyo |
July 2008 | £510 | 19.25 % |
|
Boehringer Ingelheim |
July 2008 | £510 | 19.25 % |
|
Bayer Company Profile |
May 2007 | £249 | 19.25 % |
|
Eisai |
July 2008 | £510 | 19.25 % |
|
Gedeon Richter |
July 2008 | £510 | 19.25 % |
|
LEO Pharma |
July 2008 | £510 | 19.25 % |
|
Gruenenthal |
July 2008 | £510 | 19.25 % |
|
The Top 10 Contract Research Organizations Positioning, performance and SWOT analyses |
March 2009 | £2025 | 19.25 % |
|
Kyowa Hakko Kirin IMS Company Profile |
November 2008 | £510 | 19.25 % |
|
Mylan IMS Company Profiles |
June 2009 | £510 | 19.25 % |
|
Boehringer Ingelheim IMS Company Profiles |
June 2009 | £510 | 19.25 % |
|
Baxter IMS Company Profiles |
June 2009 | £510 | 19.25 % |
|
Pfizer IMS Company Profiles |
June 2009 | £510 | 19.25 % |
|
Roche IMS Company Profiles |
June 2009 | £510 | 19.25 % |
|
UCB IMS Company Profiles |
June 2009 | £510 | 19.25 % |
|
Solvay IMS Company Profiles |
June 2009 | £510 | 19.25 % |
|
GlaxoSmithKline IMS Company Profile |
April 2009 | £510 | 19.25 % |
|
Shionogi IMS Company Profile |
December 2008 | £510 | 19.25 % |
|
Wound Treatments in Thailand |
November 2007 | £450 | 19.25 % |
|
Johnson IMS Company Profile |
December 2008 | £510 | 19.25 % |
|
HLR IMS Company Profile |
December 2008 | £510 | 19.25 % |
|
Meiji Seika IMS Company Profile |
December 2008 | £510 | 19.25 % |
|
Ono IMS Company Profile |
December 2008 | £510 | 19.25 % |
|
Schering-Plough IMS Company Profile |
April 2009 | £510 | 19.25 % |
|
Ostuka IMS Company Profile |
December 2008 | £510 | 19.25 % |
|
Nycomed Pharma IMS Company Profile |
June 2008 | £510 | 19.25 % |
|
Astellas |
July 2008 | £510 | 19.25 % |
|
Pfizer IMS Company Profile |
July 2008 | £510 | 19.25 % |
|
Amgen IMS Company Profile |
July 2009 | £510 | 19.25 % |
|
Bristol-Myers Squibb IMS Company Profile |
February 2009 | £510 | 19.25 % |
|
Teva IMS Company Profile |
April 2009 | £510 | 19.25 % |
|
Solvay IMS Company Profile |
May 2008 | £510 | 19.25 % |
|
Roche IMS Company Profile |
April 2009 | £510 | 19.25 % |
|
Sanofi-Aventis IMS Company Profile |
April 2009 | £510 | 19.25 % |
|
Servier IMS Company Profile |
August 2008 | £510 | 19.25 % |
|
Daiichi Sankyo IMS Company Profile |
July 2009 | £510 | 19.25 % |
|
Gruenenthal IMS Company Profile |
October 2006 | £249 | 19.25 % |
|
Schwarz Pharma IMS Company Profile |
October 2006 | £249 | 19.25 % |
|
Valeant IMS Company Profile |
May 2007 | £249 | 19.25 % |
|
Novo Nordisk IMS Company Profile |
July 2009 | £510 | 19.25 % |
|
Procter & Gamble IMS Company Profile |
October 2008 | £510 | 19.25 % |
|
King Pharmaceuticals IMS Company Profile |
October 2008 | £510 | 19.25 % |
|
ISIS IMS Company Profile |
November 2008 | £510 | 19.25 % |
|
Johnson & Johnson IMS Company Profile |
February 2009 | £510 | 19.25 % |
|
Mylan IMS Company Profile |
June 2008 | £510 | 19.25 % |
|
Nestle IMS Company Profile |
April 2009 | £510 | 19.25 % |
|
Esteve IMS Company Profile |
July 2009 | £510 | 19.25 % |
|
Taisho IMS Company Profile |
February 2007 | £249 | 19.25 % |
|
Merck & Co IMS Company Profile |
October 2008 | £510 | 19.25 % |
|
South Africa Pharmaceuticals and Healthcare Report Q3 2008 |
June 2008 | £425 | 19.25 % |
|
Indian Pharmaceutical Market, 2006-2011 |
June 2006 | £1499 | 19.25 % |
|
Barr Laboratories IMS Company Profile |
June 2008 | £510 | 19.25 % |
|
Almirall IMS Company Profile |
July 2009 | £510 | 19.25 % |
|
Boehringer Ingelheim IMS Company Profile |
November 2008 | £510 | 19.25 % |
|
Biogen Idec IMS Company Profile |
July 2009 | £510 | 19.25 % |
|
Gilead Sciences IMS Company Profile |
June 2008 | £510 | 19.25 % |
|
Bayer IMS Company Profile |
April 2009 | £510 | 19.25 % |
|
Chugai IMS Company Profile |
May 2008 | £510 | 19.25 % |
|
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics |
April 2008 | £1965 | 19.25 % |
|
Wound Treatments in Sweden |
October 2007 | £450 | 19.25 % |
|
Serono IMS Company Profile |
December 2006 | £249 | 19.25 % |
|
Conducting Clinical Trials in Emerging Markets |
January 2007 | £2395 | 19 % |
|
Genzyme Corporation Deals Partneringdesk briefing |
July 2005 | £215 | 19 % |
|
Gene Therapy Technologies, Markets and Companies |
February 2010 | £2865 | 19 % |
|
Stem Cell Research Market Trends, Investment Trends and Pipeline Analysis |
February 2010 | £2230 | 18.9 % |
|
Chiral Technology International Technology & Market Trends |
November 2009 | £1905 | 18.9 % |
|
The Japanese Pharmaceutical Market Outlook to 2014 Policy environment, market structure, competitive landscape, growth opportunities |
January 2010 | £3835 | 18.9 % |
|
Monoclonal Antibodies Report Part II Companies - Holding Mabs In Portfolio Promises Protection Against The Looming 2011-12 Patent Cliff |
September 2007 | £3800 | 18.9 % |
|
Singapore Pharmaceuticals & Healthcare |
January 2007 | £395 | 18.9 % |
|
Latin American Developing Markets for Pharmaceuticals, 2006-2011 |
November 2006 | £1999 | 18.9 % |
|
Global Generics Industry Report |
September 2006 | £550 | 18.9 % |
|
Pharmaceutical Parallel Trade in the United Kingdom, 2000-2006 Market Insights and Trends in a Primary Import Destination |
August 2006 | £900 | 18.55 % |
|
Optimizing PLM Technology for the Pharmaceutical Industry (Technology Focus) |
July 2007 | £1000 | 18.55 % |
|
Innovations and Trends in Clinical Trials Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology |
March 2007 | £1430 | 18.55 % |
|
Cardiovascular Pharmaceutical Market Trends, 2007 to 2010 Key market forecasts and growth opportunities |
August 2007 | £895 | 18.55 % |
|
Innovative And Targeted Cancer Therapies Key Technologies, New Applications And Leading Players |
July 2007 | £1495 | 18.55 % |
|
Eye Care in Indonesia |
April 2009 | £560 | 18.55 % |
|
Monoclonal Antibodies Report Part I |
June 2007 | £3800 | 18.55 % |
|
Central and Eastern European (CEE) Developing Markets for Pharmaceuticals, 2006-2011 |
November 2006 | £1999 | 18.55 % |
|
Global Smoking Cessation Market Analysis & Forecasts Preparing For The First Blockbuster |
July 2007 | £1499 | 18.5 % |
|
Targeted Therapies in Oncology A World Review |
December 2006 | £4320 | 18.5 % |
|
Pfizer Inc Deals Partneringdesk briefing |
July 2005 | £215 | 18.5 % |
|
Ophthalmological Therapeutics Pipelines, Delivery Technologies, and Markets |
January 2008 | £715 | 18.5 % |
|
Drug Delivery Markets, Vol. IV: Transdermal |
April 2007 | £1590 | 18.2 % |
|
China Anti-Cancer Drug Market Report The Chinese Hospital Cancer Drug Utilization |
December 2008 | £5090 | 18.2 % |
|
Latin American Pharmaceutical Market Outlook To 2014 Policy environment, market analysis, forecasts and growth opportunities |
November 2009 | £3835 | 18.2 % |
|
Pharmaceutical Product Approval Trends, 2007 Key Market Benchmarks And Strategic Insights |
December 2007 | £995 | 18.2 % |
|
Health and Wellness Healthcare Products in Finland |
December 2006 | £650 | 18.2 % |
|
Drug Delivery Markets, Vol III Pulmonary Delivery Systems |
March 2007 | £1590 | 18.2 % |
|
Streamlining Information in the Pharmaceutical Industry with PLM (Review Report) |
August 2007 | £1795 | 18.2 % |
|
Analgesics in Indonesia |
April 2009 | £560 | 18.2 % |
|
Digestive Remedies in Indonesia |
April 2009 | £560 | 18.2 % |
|
OTC Healthcare - Kazakhstan |
April 2009 | £750 | 18.2 % |
|
Wound Treatments in Indonesia |
April 2009 | £560 | 18.2 % |
|
The Global Pain Therapeutics Market Market Analysis, R&D Pipelines and Competitive Landscape |
October 2007 | £1910 | 18 % |
|
World Vaccines Market 2008-2013 Future Forecast, Critical Trends and Developments |
April 2009 | £325 | 18 % |
|
Analytical Tool: Competitive Outlook on HCV |
July 2004 | £1310 | 18 % |
|
Vitamins and Dietary Supplements in Indonesia |
April 2009 | £560 | 17.85 % |
|
Medicated Skin Care in Indonesia |
April 2009 | £560 | 17.85 % |
|
Key Trends in Offshoring Pharmaceutical R&D Company strategies, emerging markets and impact on ROI |
March 2009 | £2025 | 17.85 % |
|
Supply chain management in pharmaceutical industry in Poland 2008 |
September 2008 | £1030 | 17.85 % |
|
China's Attraction and Strategies to Work with It Analysis of Best Strategies for Western Pharmaceutical and Biotech Companies to Partner with Chinese Pharmaceutical Companies |
July 2008 | £955 | 17.85 % |
|
China's Attraction and Strategies to Work with It Analysis of Best Strategies for Western Pharmaceutical and Biotech Companies to Partner with Chinese Pharmaceutical Comp |
July 2008 | £1020 | 17.85 % |
|
Drug Delivery Systems US Market Outlook, Advances for Pharma, Biotech & Medical Devices |
September 2006 | £1460 | 17.85 % |
|
OTC Pharmaceuticals - Top 5 Emerging Markets Industry Guide |
September 2009 | £995 | 17.85 % |
|
Future Growth Opportunities in Generics The impact of consolidation on market and competitive dynamics |
November 2006 | £1495 | 17.85 % |
|
Mid Pharma Sector In-licensing and other externalization strategies |
June 2006 | £4350 | 17.85 % |
|
Biosimilars: Benchmarking the key players With increasing regulatory clarity and high revenue potential, interest in biosimilars increases |
December 2006 | £4000 | 17.85 % |
|
Innovative Drug R&D in China |
October 2009 | £1845 | 17.85 % |
|
Big Pharma's Key Lifecycle Management Strategies Maximizing The Market Potential |
February 2010 | £2230 | 17.5 % |
|
Chinese Pharmaceutical Industry Strategies, Trends and Opportunities |
August 2005 | £3330 | 17.5 % |
|
Global. Generics |
April 2009 | £800 | 17.5 % |
|
Drug Delivery Markets, Vol II Implantable Injectable |
February 2007 | £1590 | 17.5 % |
|
Alcon Medical Device Company Intelligence Report |
November 2009 | £295 | 17.5 % |
|
Injectable Drug Delivery: Market Impact and Industry Trends |
October 2006 | £1115 | 17.5 % |
|
Neurodegenerative Market Forecast to 2013 |
February 2009 | £6360 | 17.5 % |
|
Pharmaceutical Markets in India |
April 2004 | £825 | 17.5 % |
|
Coagulation Factors 2009 Target Pipeline and Corporate Benchmark Analysis |
August 2009 | £2140 | 17.5 % |
|
Cough, Cold and Allergy (Hay Fever) Remedies in Indonesia |
April 2009 | £560 | 17.5 % |
|
Par Pharmaceutical Companies Inc.-Deals & Alliances Report |
January 2010 | £380 | 17.5 % |
|
Winning R&D Productivity Strategies Exploiting innovation, licensing and outsourcing opportunities |
October 2006 | £1495 | 17.5 % |
|
Par Pharmaceutical Companies Inc. -Deals & Alliances Report |
February 2008 | £190 | 17.5 % |
|
Comparison of Pharma Outsourcing between China and India |
July 2009 | £955 | 17.15 % |
|
Amgen Inc.: PharmaVitae Profile Healthcare |
July 2009 | £5700 | 17.15 % |
|
China Asthma Drug Market Report The Chinese Asthma Drug Drug Utilization |
May 2009 | £2865 | 17.15 % |
|
United States Pharmaceuticals and Healthcare Report Q3 2006 |
July 2006 | £395 | 17.15 % |
|
Canadian Pharmaceutical Market Outlook to 2013 olicy environment, market structure, pipeline analysis, growth opportunities |
March 2009 | £2025 | 17.15 % |
|
Johnson & Johnson Medical Device Company Intelligence Report |
August 2009 | £695 | 17 % |
|
Wireless in Healthcare 2008 The Market for Bluetooth, Rfid, Zigbee, Uwb Wwan, Wman, WLAN and Other Technologies |
May 2008 | £2230 | 17 % |
|
Cell Therapy Technologies, Markets and Companies |
February 2010 | £3185 | 17 % |
|
Personalized Medicine Scientific & Commercial Aspects |
February 2010 | £2545 | 17 % |
|
Cancer Therapeutics Markets |
May 2008 | £2165 | 16.8 % |
|
Emerging Pharmaceutical Markets Growth Opportunities, Changing Healthcare Dynamics And Regulatory Trends |
September 2007 | £1495 | 16.8 % |
|
Pharmaceutical Contract Manufacturing and Research |
May 2005 | £3085 | 16.8 % |
|
Emerging Pharmaceutical Markets Argentina and Mexico |
March 2008 | £3800 | 16.8 % |
|
Monoclonal Antibodies Report |
June 2008 | £3800 | 16.8 % |
|
Analytical Tool - Lymphoma Therapeutics & Competitive Insights |
May 2007 | £2705 | 16.5 % |
|
Analytical Tool - Analysis of Cancer Immunotherapy The World Guide |
May 2007 | £4320 | 16.5 % |
|
Analytical Tool: Lymphoma Therapeutics & Competitive Insights |
January 2010 | £2705 | 16.5 % |
|
Analytical Tool - Targeted Therapeutics: Melanoma |
January 2010 | £2705 | 16.5 % |
|
Partneringreview 2006 |
February 2006 | £2195 | 16.45 % |
|
Competitive Outlook on HCV What to Know & Expect in R&D and Business Development |
June 2004 | £870 | 16.45 % |
|
Contract Research and Manufacturing Services India (CRAMS) |
March 2008 | £600 | 16.45 % |
|
Pharmaceutical Distribution in the US Current and Future Perspectives |
July 2009 | £1495 | 16.45 % |
|
Small and Medium Biopharmaceutical Enterprises in North America and Europe Biotechnology Clusters, Funding Characteristics and Regulatory Landscape |
February 2010 | £2230 | 16.45 % |
|
Winning Pharmaceutical Brand Management Maximizing brand value through best practice in brand development and product marketing |
March 2006 | £1495 | 16.45 % |
|
Cancer Market Trends 2008 - 2012 Key market forecasts and growth opportunities |
January 2009 | £1100 | 16.45 % |
|
Outsourcing Clinical Trials A Global Analytical Guide and Comparative Analysis of International Destinations, with Location Attractiveness Index |
May 2007 | £1910 | 16.45 % |
|
Gamma/Scintillation Cameras Global Trends |
November 2009 | £1905 | 16.45 % |
|
Japanese Pharmaceutical Market 2008-2023, the |
October 2008 | £1499 | 16.1 % |
|
Indian Biopharmaceuticals |
January 2008 | £600 | 16.1 % |
|
Achieving success in the Developing Asian Pharmaceutical Sector 2007-2011 |
November 2006 | £1999 | 16.1 % |
|
Drug Delivery Markets Oral Delivery |
January 2007 | £1590 | 16.1 % |
|
Pharmaceutical Outsourcing Strategies Market expansion, offshoring and strategic management in the CRO and CMO marketplace |
April 2006 | £1495 | 16.1 % |
|
Genomics World Markets |
May 2008 | £2165 | 16.1 % |
|
Generic Series: An Introduction to the Canadian Generics Market Key trends and leading companies shaping the market |
June 2007 | £2005 | 16.1 % |
|
Bringing Drugs to Market The role of CRM in improving sales & marketing (Review Report) |
August 2007 | £1000 | 16.1 % |
|
Analytical Tool - Hematological Cancers |
May 2007 | £5190 | 16 % |
|
Analytical Tool - Prostate Cancer A Therapeutic & Competitive Insight |
January 2009 | £2705 | 16 % |
|
Analytical Tool - Melanoma |
January 2009 | £2705 | 16 % |
|
Analytical Tool - Colorectal Cancer |
January 2010 | £2705 | 16 % |
|
Analytical Tool: Competitive Outlook on Cancer Vaccines |
January 2010 | £2705 | 16 % |
|
Analytical Tool - Breast Cancer |
January 2009 | £2705 | 16 % |
|
Analytical Tool - Cancer Vaccines |
January 2009 | £2705 | 16 % |
|
Analytical Tool - Peptides in Oncology |
January 2010 | £2705 | 16 % |
|
Analytical Tool: Breast Cancer R&D Comprehensive Guide |
January 2010 | £2705 | 16 % |
|
Analytical Tool - Leukemia Therapeutics & Competitive Insights |
January 2010 | £2705 | 16 % |
|
Analytical Tool: Prostate Cancer A Therapeutic & Competitive Insight |
January 2010 | £2705 | 16 % |
|
Analytical Tool: Apoptosis Promise or deception? |
January 2010 | £2705 | 16 % |
|
Winning Product Launch Strategies Maximizing sales from new pharmaceutical products |
April 2007 | £1495 | 15.75 % |
|
Lundbeck Pharmaceutical Company Intelligence Report Performance, Products, Pipeline and Potential |
March 2009 | £595 | 15.75 % |
|
Gene Expression Reagents Markets |
April 2007 | £1270 | 15.75 % |
|
Direct to Consumer (DTC) Advertising in Pharmaceuticals Current and Future Market Outlook, Regulatory Landscape and Case Studies |
December 2009 | £2230 | 15.75 % |
|
Analytical Tool: Protein Kinase Inhibitors in Oncology |
January 2010 | £3100 | 15.5 % |
|
Drug Delivery Technologies: Players, products & prospects to 2015 |
November 2007 | £1795 | 15.5 % |
|
Analytical Tool: Analysis of Cancer Immunotherapy The World Guide |
January 2010 | £4320 | 15.5 % |
|
Analytical Tool – Hematological Cancers |
January 2010 | £5190 | 15.5 % |
|
Analytical Tool - Targeted Therapeutics: Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer |
May 2007 | £2705 | 15.5 % |
|
Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology |
January 2010 | £2705 | 15.5 % |
|
The Vaccines 2008 World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry |
April 2008 | £2610 | 15.5 % |
|
Analytical Tool: The Commercial Success of Cancer Therapeutic Antibodies |
January 2010 | £3490 | 15.5 % |
|
Analytical Tool - Protein Kinase Inhibitors in Oncology |
January 2009 | £2705 | 15.5 % |
|
Analytical Tool - Cancer Therapeutic Antibodies |
January 2009 | £3580 | 15.5 % |
|
Analytical Tool - Angiogenesis in Oncology |
January 2009 | £2705 | 15.5 % |
|
Analytical Tool - Apoptosis in Oncology |
January 2009 | £2705 | 15.5 % |
|
Product Lifecycle Management, 2006 |
May 2006 | £1499 | 15.4 % |
|
RNA Interference for Drug R&D Applications, Alliances, Companies and WW Market to 2011 |
July 2007 | £1650 | 15.4 % |
|
Mexico Diabetes Care Devices Market Analysis & Forecasts to 2015 |
January 2009 | £2230 | 15.4 % |
|
Contract Pharmaceutical Manufacturing, Research, and Packaging |
August 2007 | £3085 | 15.4 % |
|
Top 10 Generic Pharmaceutical Companies, The Positioning, Performance and SWOT Analyses |
July 2008 | £1995 | 15.4 % |
|
Healthcare and Pharmaceuticals in Latin America A guide to the markets and regulations |
May 2005 | £525 | 15.4 % |
|
The Global Drug Delivery Market Research Trends and Market Outlook |
May 2006 | £1270 | 15.4 % |
|
Next-Generation Nutraceuticals Food and pharma convergence in disease prevention and personalized nutrition |
December 2006 | £1495 | 15.4 % |
|
Contract Manufacturing Strategies Market developments, technology transfer and key success factors |
May 2008 | £2325 | 15.4 % |
|
Biotech 2010 |
June 2006 | £3085 | 15.05 % |
|
Manufacturing in the Global Pharmaceuticals Industry Key drivers, company strategies and regulations (3rd Edition) |
September 2008 | £899 | 15.05 % |
|
Commercializing Molecular Diagnostics: Products, Services, Companies and Global Market |
July 2008 | £1650 | 15.05 % |
|
Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006 |
March 2006 | £1270 | 15.05 % |
|
China Senile Dementia Drug Market Report The Chinese Dementia Drug Utilization |
March 2009 | £5090 | 15.05 % |
|
Pediatric Drug Delivery Technology and Product Opportunities |
February 2009 | £1650 | 15.05 % |
|
A Guide to Biosimilars, Biogenerics and Follow-on Biologics |
January 2007 | £1095 | 15.05 % |
|
South and Central America Anesthesia and Respiratory Devices Investment Opportunities, Analysis and Forecasts to 2015 |
June 2009 | £1590 | 15.05 % |
|
Reaching Doctors and Patients Through New Digital Media |
January 2008 | £2005 | 15.05 % |
|
Pricing & Reimbursement of Medicines in the United Kingdom Understanding the pharmaceutical market in the healthcare system |
June 2005 | £450 | 15.05 % |
|
Cancer Therapies: Technologies and Global Markets |
January 2008 | £3085 | 15.05 % |
|
Drug Delivery in Central Nervous System Diseases Technologies,Markets and Companies |
October 2009 | £1590 | 15 % |
|
Drug Delivery to Central Nervous System Diseases Technologies, Markets and Companies |
February 2010 | £1780 | 15 % |
|
Freeze Drying Equipment A Global Market Perspective |
November 2009 | £1905 | 14.7 % |
|
Commercial Insight: Antihormonal Cancer Therapies |
July 2009 | £15200 | 14.7 % |
|
Clinical Trials Market 2006, The |
February 2006 | £1499 | 14.7 % |
|
Innovation in Drug Delivery The future of nanotechnology and non-invasive protein delivery |
November 2006 | £1495 | 14.7 % |
|
China Dermatosis Drug Market Report The Chinese Hospital Cancer Drug Utilization |
February 2009 | £5090 | 14.7 % |
|
Pharmaceutical Markets in Brazil, Russia, India and China (Bric Nations) |
July 2008 | £1125 | 14.7 % |
|
Booming Biotech Market in India |
June 2008 | £450 | 14.7 % |
|
Protease Inhibitors Innovation Drives Drug Pipeline |
February 2009 | £2385 | 14.7 % |
|
Innovations in Diagnostics |
September 2006 | £1495 | 14.7 % |
|
Commercial Insight: Epilepsy Companies Committed To The Cause Will Reap The Benefits |
September 2007 | £7600 | 14.7 % |
|
Manufacturing & Supply Agreements in Pharma, Biotech and Diagnostics 2nd Edition |
July 2009 | £1195 | 14.5 % |
|
Parallel Trade US Lawmakers Allow Imported Prescriptions Drugs |
June 2007 | £1499 | 14.35 % |
|
How to React to Parallel Trade |
January 2007 | £1095 | 14.35 % |
|
Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The |
January 2007 | £1430 | 14.35 % |
|
Gas Chromatography Systems World Review |
November 2009 | £1905 | 14.35 % |
|
Asia Pacific Anesthesia and Respiratory Devices Investment Opportunities, Analysis and Forecasts to 2015 |
June 2009 | £1590 | 14.35 % |
|
OTC Healthcare in Slovenia |
February 2009 | £750 | 14.35 % |
|
Global Antivirals Market Analysis & Forecasts 2008-2023 |
September 2008 | £1499 | 14.35 % |
|
China Hypertension Drug Market Report The Chinese Hospital Cancer Drug Utilization |
February 2009 | £5090 | 14.35 % |
|
Innovations in The Management of Diabetes Next generation treatments and market dynamics |
June 2008 | £1995 | 14.35 % |
|
Ophthalmic Pharmaceutical Drugs A Global Market Perspective |
November 2009 | £1905 | 14.35 % |
|
Israel Diabetes Care Devices Market Analysis & Forecasts to 2012 |
January 2009 | £2230 | 14.35 % |
|
Generic Competition, 2007–11 The impact of patent expiries on sales of major drugs |
February 2007 | £1375 | 14.35 % |
|
Roche: Pipeline, Products, Performance, Potential |
November 2007 | £595 | 14 % |
|
Veterinary Health Markets |
December 2008 | £2165 | 14 % |
|
Drug Delivery Series I-IV |
April 2007 | £4550 | 14 % |
|
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products |
August 2007 | £8010 | 14 % |
|
Commercial Insight: Cardiovascular and metabolic market overview Diabetes to the fore as generics hit primary care markets |
February 2009 | £8000 | 14 % |
|
World Contract Research and Manufacturing Market, 2006-2011, The Trends in Outsourcing |
August 2006 | £1499 | 14 % |
|
Global Generics Guide Benchmarking the key players |
April 2006 | £4000 | 14 % |
|
Licensing Strategies - Examining Todays Pharmaceutical Licensing Trends |
November 2007 | £7600 | 14 % |
|
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023 |
May 2008 | £1499 | 14 % |
|
Innovations In Epigenetics Advances in Technologies, Diagnostics & Therapeutics |
November 2009 | £3835 | 14 % |
|
Nissan Chemical Industries, Ltd. - Financial and Strategic Analysis Review |
June 2009 | £80 | 13.65 % |
|
Generics Global Industry Guide |
October 2010 | £1495 | 13.65 % |
|
Medical Plastics A Worldwide Market Review |
November 2009 | £1905 | 13.65 % |
|
GPCRs: Dawn of a New Era? |
October 2008 | £2385 | 13.65 % |
|
Ribonucleic Acid (RNA) Therapeutics Strong Potential to Address Unmet Needs in Pharma |
February 2010 | £2230 | 13.65 % |
|
Pharmaceutical Pricing and Reimbursement Reference Pricing and Economic Evaluations Will Dominate Future Pricing and Reimbursement Strategies |
February 2010 | £2230 | 13.65 % |
|
Peptic Ulcer Testing A World Market Intelligence Report |
November 2009 | £1905 | 13.65 % |
|
Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics |
February 2009 | £1195 | 13.5 % |
|
Stem Cells - The hype and the hope Business opportunities and forecasts |
January 2007 | £4999 | 13.5 % |
|
Nanobiotechnologies Applications, Markets and Companies |
May 2009 | £2545 | 13.5 % |
|
Pharmaceutical Branding Strategies Thought leader perspectives on brand building, effective communication and future brand models |
January 2006 | £1495 | 13.3 % |
|
Business Blogging for Pharma |
August 2007 | £2005 | 13.3 % |
|
The Future of Contract Manufacturing Market Forecasts to 2015 |
December 2009 | £2230 | 13.3 % |
|
The U.S. Market for EMR Technologies |
January 2007 | £2545 | 13.3 % |
|
Indian Pharmaceutical Industry |
July 2008 | £1270 | 13.3 % |
|
Tanabe Prospects to 2010 Pipeline, Products,Performance,Potential |
September 2007 | £595 | 13.3 % |
|
Laboratory Glassware and Plasticware Global Market Opportunities |
November 2009 | £1905 | 13.3 % |
|
World Generics Market 2006-2011; The |
May 2006 | £1499 | 13.3 % |
|
The Global OTC Pharmaceutical Market 2009-2024 |
May 2009 | £1499 | 13.3 % |
|
Protein Therapeutics Markets (Antithrobins, Cytokines, Growth Hormones, Hematopoietics, Insulin, Monoclonal Antibodies, Plasma Proteins, Vaccines, and Other Treatments) |
December 2008 | £2225 | 13.3 % |
|
Molecular Diagnostics A Dynamic and Rapidly Broadening Market Overview |
January 2009 | £2385 | 13.3 % |
|
Emerging Markets Series: The Pharmaceutical Market of South Korea |
October 2008 | £4000 | 13.3 % |
|
CNS Biomarkers: Players, products and prospects (Volume II) |
August 2008 | £595 | 13.3 % |
|
Bioinformatics Report The forecasts and future of the market 2006-2011 |
October 2006 | £1499 | 13.3 % |
|
Booming Clinical Trials Market in India |
November 2007 | £765 | 13.3 % |
|
Colorectal Cancer: Pipeline/Commercial Insight Shaping the future dynamics of colorectal cancer management |
October 2006 | £8000 | 13.3 % |
|
The Future of Oncology Therapeutics Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis |
December 2009 | £2230 | 13.3 % |
|
AstraZeneca Pharmaceuticals, Company Profile and Healthcare |
June 2008 | £595 | 13.3 % |
|
Monoclonal Antibodies 2007 Competitive Landscape & Pipeline Insight |
January 2007 | £1430 | 13.3 % |
|
Disease Management and Drug Adherence Strategies to support patients and enhance treatment persistence |
July 2007 | £3800 | 13.3 % |
|
Pain Management Global Trends |
November 2009 | £1905 | 13.3 % |
|
Commercial Opportunities from Biomarkers Transforming drug discovery, clinical development and molecular diagnostic |
May 2006 | £1495 | 13.3 % |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1700 | 13 % |
|
Medical Imaging: Reagents and Analysis Tools |
December 2006 | £3085 | 12.95 % |
|
The Future of Targeted Therapeutics Key Technologies, New Therapy Area Applications and Leading Players |
March 2008 | £1995 | 12.95 % |
|
World Generics Market, 2008-2013 |
November 2008 | £1499 | 12.95 % |
|
Pharmaceutical Licensing Strategies Best practices in deal-making, valuations and strategic management |
June 2006 | £1495 | 12.95 % |
|
Sterilization Technologies Advancing in the 21st Century |
October 2005 | £3085 | 12.95 % |
|
Hplc Systems & Accessories A World Market Review |
November 2009 | £1905 | 12.95 % |
|
Drug Delivery Technology: Revolutionizing CNS Therapies |
December 2007 | £945 | 12.95 % |
|
Bristol-Myers Squibb Pipeline, Products, Performance, Potential |
February 2008 | £595 | 12.95 % |
|
World OTC Pharmaceutical Markets Self-Medication, Developing and Petro-Rich Economies, BTC and Other Growth Trends |
May 2008 | £2035 | 12.95 % |
|
Monoclonal Antibodies in Cancer Therapy 2009-2024 |
May 2009 | £1499 | 12.95 % |
|
Shionogi: Pipeline - Products - Performance - Potential |
March 2008 | £595 | 12.95 % |
|
Biomarkers in Drug Discovery Optimizing Drug Discovery Timeline and Costs |
February 2010 | £2230 | 12.6 % |
|
Stakeholder Opinions Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies |
July 2008 | £3800 | 12.6 % |
|
Pharmaceutical Pricing And Reimbursement Strategies For Market Access Across The Us, Europe, Japan And Other Key Geographies |
November 2007 | £1495 | 12.6 % |
|
World Asthma and COPD Treatment Market, 2006-2011, The A Changing Market with Increasing Potential |
September 2006 | £1499 | 12.6 % |
|
Evolving Trends in Biopharmaceutical Licensing Deal assessments, drivers and resistors |
March 2009 | £2025 | 12.6 % |
|
Negotiating The Emerging Biosimilars Landscape Key Developments in The Regulatory Environment |
February 2009 | £2025 | 12.6 % |
|
Global Medical Markets for Nanoscale Materials and Devices |
January 2008 | £3085 | 12.6 % |
|
The Future of e-Clinical Trial Solutions Market Forecasts to 2015 |
December 2009 | £2230 | 12.6 % |
|
Biotechnological Innovations In The Pharmaceutical Industry in Poland 2009 Development forecasts for biotechnology sector for 2009-2011 |
August 2009 | £1745 | 12.6 % |
|
Currently Druggable in Colorectal Cancer A Drug Target Competitive Analysis |
December 2008 | £1700 | 12.5 % |
|
Strategic Management of Resources and Portfolios Structuring Risk to Maximize Opportunity in Pharmaceutical R&D |
August 2008 | £2385 | 12.25 % |
|
Global Markets for Antifungal Agents |
March 2007 | £3085 | 12.25 % |
|
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The Challenge Of Turning Technology Into Therapy |
July 2007 | £1999 | 12.25 % |
|
The Future of Biobanks Regulation, ethics, investment and the humanization of drug discovery |
March 2009 | £2025 | 12.25 % |
|
M&A trends in Pharma |
October 2008 | £6000 | 12.25 % |
|
Patient Monitoring Markets |
October 2009 | £2165 | 12.25 % |
|
Delivering RNAi-Based Therapeutics & Diagnostics Challenges & Opportunities |
July 2009 | £945 | 12.25 % |
|
Pipeline Insight: Breast Cancer Recent approvals increase pressure on pipeline candidates |
April 2008 | £6000 | 12.25 % |
|
Animal Therapeutics and Diagnostics |
January 2008 | £3085 | 12.25 % |
|
Hematology Analyzer Instrumentation and Reagent Markets |
July 2009 | £2165 | 12.25 % |
|
Delivering New Biopharmaceutical Therapies Challenges & Opportunities |
January 2009 | £945 | 12.25 % |
|
Biomanufacturing Strategies Market Drivers, Build-Vs-Buy Decisions And Opportunities In Contract Relationship Management |
September 2007 | £1495 | 12.25 % |
|
Biochips A Global Update of Market Trends & Opportunities |
November 2009 | £1905 | 12.25 % |
|
The Global Pain Market 2008-2023 |
November 2008 | £1499 | 12.25 % |
|
Diabetes, Metabolic Syndrome and Cardiovascular Disease Reshaping Tomorrow's Diabetes Market |
October 2005 | £1270 | 12.25 % |
|
DNA Sequencing and PCR Markets |
July 2007 | £2165 | 12.25 % |
|
Stakeholder Opinions: Diagnostics in Neurology Predictive Biomarkers Expand Drug Revenues |
July 2008 | £2005 | 12.25 % |
|
Commercial Insight: Antihypertensives New challenges for a maturing market |
September 2006 | £8000 | 12.25 % |
|
eHealth Solutions for Pharma Strategies for salesforces, marketing, patient compliance and clinical trials |
March 2007 | £1495 | 12.25 % |
|
Indian Pharmaceutical Industry, The: |
March 2005 | £3335 | 12.25 % |
|
Biomarkers: The Future of Next-Generation Drug R&D |
September 2008 | £1650 | 12.25 % |
|
Eisai Pipeline - Products - Performance - Potential |
June 2008 | £595 | 12.25 % |
|
Electrophoresis Equipment & Supplies A World Market Review |
November 2009 | £1905 | 12.25 % |
|
The Future of Contract Research Outsourcing Market Forecasts to 2015, Geographical Landscape and Competitive Benchmarking |
December 2009 | £2230 | 12.25 % |
|
Effective Deal Making in Drug Delivery |
April 2009 | £3594 | 12.25 % |
|
Disposable Syringe Markets Trends, Industry Participants, Product Overviews and Market Drivers |
October 2009 | £2165 | 12.25 % |
|
Rx market in Poland 2006 Development forecasts 2006-2008 |
November 2006 | £1350 | 12.25 % |
|
Indian Healthcare - New Avenues for Growth |
October 2008 | £510 | 12.25 % |
|
Pfizer Market Outlook for a Global Leader, 2008-2013 |
August 2008 | £1499 | 12.25 % |
|
World Market for Prescription Generic Drugs; The 5th Edition |
April 2006 | £2230 | 11.9 % |
|
Medical and Biological Sensors and Sensor Systems Markets, Applications, and Competitors Worldwide, 2nd Edition |
May 2006 | £2230 | 11.9 % |
|
Market for Bioengineered Protein Drugs; The |
January 2007 | £3085 | 11.9 % |
|
Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics 2009-2023 |
January 2009 | £1499 | 11.9 % |
|
Emerging Cancer Vaccine Market, The 2nd Edition |
November 2006 | £2230 | 11.9 % |
|
World Market for Pain Management Drugs and Devices 2nd Edition |
December 2006 | £2230 | 11.9 % |
|
The Impact of the Phase III Pipeline Future Projections and Market Disruptions |
March 2006 | £2230 | 11.9 % |
|
Pharmaceutical Outsourcing Opportunities Post Launch Contract Manufacturing, and Sales and Marketing,2nd Edition |
September 2006 | £2480 | 11.9 % |
|
Nanotechnology Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics |
January 2008 | £1995 | 11.9 % |
|
Global Market for Adjunctive Therapies in Cancer, The 2nd Edition |
April 2006 | £2230 | 11.9 % |
|
China Pharma Outsourcing Annual Review 2009 |
November 2009 | £880 | 11.9 % |
|
The Worldwide Market for Cancer Diagnostics 3rd Edition |
March 2008 | £2545 | 11.9 % |
|
World Market for Prescription Gastrointestinal Drugs, The |
July 2006 | £2230 | 11.9 % |
|
Fastest Growing Biotechnology Companies, The Growth Strategies, Comparative Analyses and Company Profiles |
March 2008 | £1995 | 11.9 % |
|
World Market for Prescription Respiratory Drugs, The |
October 2006 | £2230 | 11.9 % |
|
World Market for Prescription Orthopedic Drugs, The |
October 2006 | £2230 | 11.9 % |
|
Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth |
October 2008 | £8000 | 11.9 % |
|
World Market for Psychotherapeutic Drugs, The |
January 2007 | £2230 | 11.9 % |
|
Biomarkers, Tests and Trends for Drug R&D |
February 2010 | £1530 | 11.9 % |
|
Drug Delivery Technology: Revolutionizing Cardiovascular Therapies |
July 2007 | £945 | 11.9 % |
|
Japan in Vitro Diagnostics Investment Opportunities Analysis and Forecasts to 2015 |
April 2009 | £1590 | 11.9 % |
|
Commercial Insight: Antihormonal Therapy Cancer Brands Careful Lifecycle Management Needed to Preserve Brand Dominance |
August 2008 | £7600 | 11.9 % |
|
Syringes (Disposable and Reusable) Global Market Opportunities |
November 2009 | £1905 | 11.9 % |
|
BioChips & BioMEMS (Bio Microelectromechanical Systems) World Markets, Applications & Opportunities 2006-2011 Analysis & Forecasts |
May 2006 | £1145 | 11.55 % |
|
Biotech Drug Delivery Systems Key Company Intelligence & Market Outlook to 2012 |
February 2007 | £1299 | 11.55 % |
|
Advanced Drug Delivery Systems: New Developments, New Technologies |
October 2006 | £3085 | 11.55 % |
|
Pharmacovigilance Risk Management in Practice |
July 2006 | £1499 | 11.55 % |
|
Pharmaceutical Wholesale and Distribution Industry Outlook & Analysis 2008, The |
June 2008 | £1499 | 11.55 % |
|
Parallel Trade in Europe and the US The challenges facing pharma |
April 2006 | £3690 | 11.55 % |
|
Global Cardiovascular Drugs Market 2009-2024 |
June 2009 | £1499 | 11.55 % |
|
Molecular Diagnostics A World Market Review |
November 2009 | £1905 | 11.55 % |
|
World Sleep Disorders Market Analysis 2009-2024 |
June 2009 | £1499 | 11.55 % |
|
Botanical and Plant-Derived Drugs Global Markets |
February 2009 | £3085 | 11.55 % |
|
China Pharma Outsourcing Market By 2015 |
January 2009 | £1110 | 11.55 % |
|
Chinese Markets for Biotechnology |
August 2006 | £2545 | 11.55 % |
|
Point of Care Diagnostic Testing Sector Trends |
June 2009 | £2165 | 11.55 % |
|
Clinical Trials Business; The |
August 2006 | £3085 | 11.55 % |
|
Executive Summary of the BioChips & BioMEMS (Biomedical Microelectromechanical Systems) Markets 2006-2011 Analysis & Forecasts |
May 2006 | £695 | 11.55 % |
|
Technology Transfer Strategies: Maximizing the returns from new technologies |
February 2009 | £2025 | 11.5 % |
|
Option & Evaluation Agreements in Pharma and Biotech |
March 2009 | £995 | 11.5 % |
|
GSK's Cervarix A Future Blockbuster of 2007 |
March 2007 | £1999 | 11.5 % |
|
World AMD and Diabetic Retinopathy Pharmaceutical Market 2009-2024 |
July 2009 | £1499 | 11.2 % |
|
Dainippon Sumitomo Pharma Co., Ltd. - Financial and Strategic Analysis Review |
July 2009 | £80 | 11.2 % |
|
Global Clinical Trial Business Report & Analysis 2008-2018 |
July 2008 | £1499 | 11.2 % |
|
Drug Delivery Technology Revolutionizing Diabetes Treatment |
September 2007 | £945 | 11.2 % |
|
Pipeline Insight: Colorectal Cancer Growing trend towards personalized medicine |
October 2010 | £11400 | 11.2 % |
|
Diabetes Therapies & Diagnostics: Global Markets |
January 2008 | £3085 | 11.2 % |
|
Global Ophthalmic Market Analysis & Forecasts to 2012 |
April 2007 | £1499 | 11.2 % |
|
World Respiratory Disorders Market 2009-2024 |
June 2009 | £1499 | 11.2 % |
|
The US Pharmaceutical Market 2009-2024 |
November 2009 | £1499 | 11.2 % |
|
Astellas Pharma: Pipeline, Products, Performance, Potential |
November 2007 | £595 | 11.2 % |
|
Pharma R&D Fact Book, The 2006 |
November 2007 | £495 | 11.2 % |
|
Drug Discovery Tools for High-Content Analysis |
July 2007 | £1270 | 11.2 % |
|
Antibiotics Global Trends |
November 2009 | £1905 | 11.2 % |
|
Anti-Obesity Drugs Trends & Opportunities Worldwide |
November 2009 | £1905 | 11.2 % |
|
Drug Delivery Technology: Revolutionizing Diabetes Treatment |
September 2007 | £945 | 11.2 % |
|
Early Stage and Discovery Deals Strategy, Structure and Payment Terms 2nd Edition |
December 2006 | £1880 | 11.2 % |
|
Commercial Insight: Cardiovascular market overview Raft of patent expires threaten blockbusters |
October 2007 | £7600 | 11.2 % |
|
Worldwide Influenza Market; The |
May 2006 | £3085 | 11.2 % |
|
Commercial Insight: Antithrombotics Market expands as disease management focuses on prevention |
October 2007 | £7600 | 11.2 % |
|
Pricing and Reimbursement in Key Asia Pacific Markets |
January 2009 | £2000 | 11.2 % |
|
CNS Therapeutics A World Market Review |
November 2009 | £1905 | 11.2 % |
|
China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012 |
May 2008 | £1910 | 11.2 % |
|
Avian Influenza |
August 2006 | £635 | 11.2 % |
|
Medical Device Coatings |
November 2008 | £3085 | 11 % |
|
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 |
June 2007 | £1999 | 11 % |
|
Commercial Insight: Migraine Opportunities Will Exist In The Wake Of Generic Attack |
September 2007 | £7600 | 10.85 % |
|
Bioinformatics Markets Strategies, Business Models and Trends for the Future |
March 2009 | £2165 | 10.85 % |
|
RNA Interference Markets |
December 2008 | £2165 | 10.85 % |
|
Anti-Obesity Treatments Analysis & Forecasts 2009-2024 |
February 2009 | £1499 | 10.85 % |
|
Disposable Medical Supplies Markets |
August 2009 | £2165 | 10.85 % |
|
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012 |
April 2007 | £1499 | 10.85 % |
|
Contract Pharma 2008-2023 |
August 2008 | £1499 | 10.85 % |
|
Therapeutic Monoclonal Antibodies Report 2008-2023 |
July 2008 | £1499 | 10.85 % |
|
Clinical Trials: World Market 2009-2024 |
July 2009 | £1499 | 10.85 % |
|
Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in Personalized Medicine) |
June 2008 | £1905 | 10.85 % |
|
Pipeline Insight: Benign Prostatic Hyperplasia - Novel therapeutics and reformulations will drive market growth |
April 2009 | £6000 | 10.5 % |
|
Mass Spectrometry in Protein Biomarker Applications Software, Services, and Instrument Markets |
November 2006 | £1905 | 10.5 % |
|
Optimizing Sales Force Effectiveness - From quantity to quality From quantity to quality |
November 2006 | £4000 | 10.5 % |
|
Global Biotech Market Analysis and Forecasts, 2008-2023 |
August 2008 | £1499 | 10.5 % |
|
Worldwide Point of Care (POC) Are Decentralized Clinical Diagnostics a Cost Drain or Revenue Driver? |
November 2006 | £1905 | 10.5 % |
|
Medical Imaging Markets, Volume III Ultrasound |
October 2006 | £1905 | 10.5 % |
|
Biophotonics A Strategic Assessment of Photonics Technologies for Biomedical Applications |
November 2006 | £1905 | 10.5 % |
|
Microplate Instrumentation & Supplies A Global Market Perspective |
November 2009 | £1905 | 10.5 % |
|
Critical Care Pharmaceutical Markets A Strategic Analysis |
June 2006 | £1905 | 10.5 % |
|
Osteoporosis & Bone Metabolism Disorders Market 2008-2023 |
August 2008 | £1499 | 10.5 % |
|
World Dermatological Market Outlook, 2009-2023, The |
January 2009 | £1499 | 10.5 % |
|
Commercial Insight: Neuropathic Pain A Plethora of Patient Segmentation and Product Differentiation Opportunities |
July 2006 | £8440 | 10.5 % |
|
Medical Imaging Markets, Volume II Magnetic Resonance |
September 2006 | £1905 | 10.5 % |
|
Sleep Disorders Insomnia, Sleep Apnea, Restless Leg Syndrome, Bruxism, Narcolepsy and Sleepwalking |
March 2009 | £2165 | 10.5 % |
|
Cell-Based Assays for Drug Discovery |
August 2009 | £2165 | 10.5 % |
|
Commercial Insight: Pain Market Overview Non-Traditional Analgesics and Opioid Reformulations to Sustain Sector Growth |
October 2008 | £8000 | 10.5 % |
|
Probiotics A Global Update of Market Trends & Opportunities |
November 2009 | £1905 | 10.5 % |
|
Sales Force Effectiveness |
September 2008 | £4000 | 10.5 % |
|
Spain Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012 |
May 2008 | £1910 | 10.15 % |
|
The World Market for Gynaecology 2007-2017 |
September 2007 | £3200 | 10.15 % |
|
Biomarker Technology Platforms for Cancer Diagnoses and Therapies |
April 2008 | £2165 | 10.15 % |
|
Herbal Supplements, Prescription Drugs, Rx-to-OTC Products A Comparison |
October 2006 | £3085 | 10.15 % |
|
Stakeholder Opinions: Skin and soft tissue infections |
July 2009 | £3800 | 10.15 % |
|
Molecular Diagnostics Markets |
September 2008 | £2165 | 10.15 % |
|
Multiple Myeloma Therapeutics US Market Trends & Analysis |
November 2009 | £1905 | 10.15 % |
|
Pfizer Prospects to 2010 Pipeline, Products,Performance,Potential |
September 2007 | £595 | 10.15 % |
|
The World Dermatological Market Outlook 2010-2024 |
November 2009 | £1499 | 10.15 % |
|
Stakeholder Opinions: Cancer Cachexia Higher profile needed to unlock market potential of neglected syndrome |
January 2009 | £2000 | 10.15 % |
|
Veterinary diagnostics and equipment The global market |
January 2006 | £795 | 10.15 % |
|
Reducing Medical Error and Improving Diagnostics through Digital Imaging (Review Report) |
February 2007 | £1795 | 10.15 % |
|
Pharmacodiagnostics and Personalized Medicine 2009 (Markets, Challenges, Forecasts and Key Players) |
April 2004 | £2230 | 10.15 % |
|
Healthcare in a Recession (OTC, Generics, Out of Pocket Spending, Healthcare Legislation, Retail Clinics, Outsourcing and Other Topics) |
March 2003 | £1270 | 10.15 % |
|
World Neurodegenerative Diseases Market 2009-2024 |
September 2009 | £1499 | 10 % |
|
Nanomedicine 2006-2011 |
June 2006 | £1499 | 9.8 % |
|
GenericHandbook - Third Edition (2009) A Guide to the Generic Drug Industry in the US |
April 2009 | £475 | 9.8 % |
|
OTC market in Poland 2007 Development forecasts 2007-2009 |
June 2007 | £1440 | 9.8 % |
|
The Global Antivirals Market R&D Pipelines, Market Analysis and Competitive Landscape |
May 2007 | £1590 | 9.8 % |
|
United States Drug Delivery Devices Investment Opportunities Analysis and Forecasts to 2012 |
September 2008 | £1910 | 9.8 % |
|
The Pharmaceutical Industry 2008 Current and Future Trends and Strategic Issues Shaping Pharma |
March 2008 | £3010 | 9.8 % |
|
Pricing and Reimbursement in the US Innovation and robust pharmacoeconomic analysis are ke |
June 2006 | £6495 | 9.8 % |
|
Infectious Diseases Drugs Markets |
October 2009 | £2165 | 9.8 % |
|
Pipeline Insight: Insulin Antidiabetics Return to Injections Alternative Delivery Methods Fall by The Wayside |
July 2008 | £6000 | 9.8 % |
|
Rx-to-OTC Strategies Maximizing The Commercial Potential of An Rx-to-OTC Switch |
June 2008 | £2995 | 9.8 % |
|
Global Market for Antimicrobials and Antifungals; The Challenging Resistance to 2016 |
December 2006 | £1600 | 9.8 % |
|
Bioinformatics Technical Status and Market Prospects |
August 2005 | £3085 | 9.8 % |
|
Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing Using Analytics and Metrics to Improve the Bottom Line |
March 2007 | £997 | 9.8 % |
|
Biomarkers The Expanding Global Market |
November 2007 | £3085 | 9.8 % |
|
Global Generics Guide: Part 2 Benchmarking country markets and strategic issue |
June 2006 | £8695 | 9.8 % |
|
Pipeline Insight: Non-insulin Antidiabetics Type 2 diabetes unlikely to develop into a switch market |
August 2006 | £6495 | 9.8 % |
|
Asia Pacific Biotechnology Market 2007-2010 |
June 2007 | £1020 | 9.45 % |
|
World Pharmaceutical Packaging Forecasts For 2011 & 2016 For 18 Countries |
July 2007 | £3690 | 9.45 % |
|
Chemotherapy Market Insights, 2006-2016 A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities |
April 2006 | £1900 | 9.45 % |
|
Commercial and Pipeline Insight: Systemic antifungals |
November 2007 | £7600 | 9.45 % |
|
Approaches to Reducing Phase II Attrition |
May 2009 | £2385 | 9.45 % |
|
Anti-Obesity Treatments 2007-2012 - A blockbuster target market |
July 2007 | £1799 | 9.45 % |
|
Biosimilars and Follow-On Biologics Report The Global Outlook 2009-2024 |
April 2009 | £1499 | 9.45 % |
|
Asia Pacific Biotechnology Market 2007-2010 |
June 2007 | £505 | 9.45 % |
|
Pharmacy Automation: Technologies and Global Markets |
January 2008 | £3085 | 9.45 % |
|
Bio-Device Licensing: Strategies for Success |
January 2006 | £1095 | 9.45 % |
|
Proteomics Technologies, Markets and Companies |
February 2010 | £2865 | 9.45 % |
|
Asia Pacific Biotechnology Market 2007-2010 |
June 2007 | £505 | 9.45 % |
|
Sleep Apnea Diagnostic & Therapeutic Devices Worldwide |
August 2008 | £1590 | 9.45 % |
|
World Market for Prescription Cardiovascular Drugs 2nd Edition |
November 2007 | £2545 | 9.45 % |
|
Commercial & Pipeline Insight: Hospital Antibacterials A market beyond MRSA |
August 2007 | £8010 | 9.45 % |
|
Cardiotoxicity: Issues, Technologies, and Solutions for the Future |
May 2008 | £2385 | 9.45 % |
|
Dermocosmetics market in Poland 2008 Development forecasts for 2008-2010 |
November 2008 | £1485 | 9.1 % |
|
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries |
July 2007 | £7600 | 9.1 % |
|
Pricing and Reimbursement in Japan Costly healthcare system inefficiencies increase the focus on healthcare cost containment |
November 2006 | £2005 | 9.1 % |
|
The Market for In Vitro Toxicology Testing |
March 2007 | £3085 | 9.1 % |
|
Membrane Bioreactors |
July 2009 | £2515 | 9.1 % |
|
Online Pharmaceutical Industry, 2006-2011, The |
July 2006 | £1499 | 9.1 % |
|
Cancer Cell Therapy Markets |
March 2008 | £2165 | 9.1 % |
|
Pharmaceutical Pricing and Distribution in Japan The keys to success in the world's second largest market |
June 2008 | £1450 | 9.1 % |
|
Multiplex Assays in Translational Medicine Technologies, Applications, and Future Directions |
February 2008 | £715 | 9.1 % |
|
Stem Cell Therapies and Regenerative Medicine Current Applications and Future Possibilities |
December 2005 | £3085 | 9.1 % |
|
Cancer Diagnostic Testing World Markets |
April 2008 | £2165 | 8.75 % |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £1905 | 8.75 % |
|
Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
November 2009 | £1905 | 8.75 % |
|
Dental Products in China Industry forecasts for 2012 & 2017 |
January 2009 | £3245 | 8.75 % |
|
Drug Registration in China A comprehensive overview of procedures |
September 2008 | £495 | 8.75 % |
|
Companion Biomarkers in Drug Development |
April 2009 | £2165 | 8.75 % |
|
Companion Diagnostics in Personalized Medicine and Cancer Therapy |
April 2008 | £2165 | 8.75 % |
|
Medical Nanotechnology Markets |
September 2008 | £2165 | 8.75 % |
|
Pharmaceutical Counterfeiting in The Eu Where Are We Now? |
January 2007 | £1095 | 8.75 % |
|
Pricing & Reimbursement - Seven Major Markets Update |
May 2008 | £2995 | 8.75 % |
|
Parkinson's Disease Market analysis and forecasts 2008-2012, 2017 & 2022 |
January 2008 | £1499 | 8.75 % |
|
Launch Strategies - Analyzing Market Trends and Regulatory Impacts |
August 2007 | £8010 | 8.75 % |
|
Pediatric Drugs: the Worldwide Market 3rd Edition |
December 2007 | £2545 | 8.75 % |
|
Stakeholder Opinions: Back Pain Gain competitive edge by targeting subpopulations |
March 2009 | £2000 | 8.75 % |
|
Commercial Insight: Asthma & COPD Combination Products Still Have Blockbuster Potential |
July 2007 | £7600 | 8.75 % |
|
Gastrointestinal Disorders Market Intelligence to 2012 |
May 2007 | £1499 | 8.75 % |
|
Animal Biotechnology Technologies, Markets and Companies |
February 2010 | £1590 | 8.4 % |
|
Enzymes US industry forecasts to 2010 & 2015 |
July 2006 | £2735 | 8.4 % |
|
Pharmaceutical New Product Commercialization: Preparing for Market Success |
May 2008 | £3410 | 8.4 % |
|
Cancer Therapies Global Market Opportunities |
November 2009 | £1905 | 8.4 % |
|
Stakeholder Opinion: Atopic Dermatitis A high level of unmet need creates market opportunities |
March 2007 | £2005 | 8.4 % |
|
Pipeline Insight: Heart failure Week pipeline dominated by new indications and add-on diuretics |
August 2007 | £6000 | 8.4 % |
|
Generics in Japan |
November 2009 | £1825 | 8.4 % |
|
Wound Care Products A World Market Analysis |
November 2009 | £1905 | 8.4 % |
|
Pharmaceutical Product Relaunch Preserving Market Share through Line Extension and New Market Entry Strategies |
April 2007 | £4900 | 8.4 % |
|
Access to Hospital Pharmaceutical Markets in the United Kingdom |
September 2008 | £850 | 8.4 % |
|
Emerging Technologies in Spinal Motion Preservation |
October 2006 | £1295 | 8.4 % |
|
Pipeline and Commercial Insight: Schizophrenia - Second generation depots protect market value |
October 2008 | £8000 | 8.4 % |
|
Laparoscopic Devices Market Research Report Worldwide |
June 2009 | £1270 | 8.4 % |
|
Therapeutics for Memory and Cognition Disorders |
April 2009 | £3085 | 8.4 % |
|
Pipeline and Commercial Insight: Osteoporosis Novel agents to battle for payer acceptance |
July 2009 | £15200 | 8.05 % |
|
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope Healthcare |
March 2009 | £2000 | 8.05 % |
|
Blood Banking and Blood Products Global Market Perspective |
November 2009 | £1905 | 8.05 % |
|
World Enzymes Study # 2229 |
September 2007 | £3435 | 8.05 % |
|
Commercial Insight: Asthma & COPD |
June 2009 | £15200 | 8.05 % |
|
Pain Therapeutics Drugs, Markets and Companies |
February 2010 | £2230 | 8.05 % |
|
Point of Care Diagnostic Testing World Markets |
November 2009 | £2165 | 8.05 % |
|
Live-Licensing & In-life Testing R&D Processes and Regulation for New Drugs, 2008-2020 |
January 2008 | £1499 | 8.05 % |
|
Global Protein Therapeutics Market, The Market Dynamics and Pipeline Analysis |
December 2006 | £1910 | 8.05 % |
|
Prostate Cancer Therapeutics A Global Market Perspective |
November 2009 | £1905 | 8.05 % |
|
Commercial Insight: Osteoarthritis Market sees steady growth |
December 2006 | £8000 | 8.05 % |
|
Drug Discovery Technologies A Global Update of Market Trends & Opportunities |
November 2009 | £1905 | 8.05 % |
|
Stakeholder Opinions: Hormonal Contraceptives New directions in a competitive market |
November 2006 | £2005 | 8.05 % |
|
Strategies and Solutions for Publication Planning and Execution Excellence |
September 2007 | £75 | 7.7 % |
|
Epigenomics Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics |
March 2007 | £3085 | 7.7 % |
|
Biomarkers Technologies, Markets and Companies |
February 2010 | £2865 | 7.7 % |
|
In Vitro Diagnostics Market Report & Analysis 2008-2023 |
June 2008 | £1499 | 7.7 % |
|
Partnering in the Global Generics Industry 2008: A guide to companies |
July 2008 | £595 | 7.7 % |
|
Generic League Market Analysis and Forecasts, 2007-2012, 2017 & 2022 |
February 2008 | £1999 | 7.7 % |
|
Pipeline Insight: Non-insulin antidiabetics Incretin mimetics leaders in a diverse pipeline |
May 2008 | £6000 | 7.7 % |
|
Pipeline Insight: Neuropathic Pain Emerging Drugs Fail To Capitalize In Lucrative Market |
September 2007 | £740 | 7.7 % |
|
Clinical trials in Poland 2008 Development forecasts for 2008-2010 |
June 2008 | £1375 | 7.35 % |
|
Small Molecule Kinase Inhibitors |
July 2009 | £2515 | 7.35 % |
|
Bariatric (Obesity) Care Equipment & Surgical Devices Worldwide A Market Strategy Report |
February 2006 | £1270 | 7.35 % |
|
Pricing & Reimbursement in Europe Can the drive for cost effectiveness overcome cost containment? |
October 2006 | £6000 | 7.35 % |
|
Forecast Insight: Opioids - Saturation limits the commercial potential of individual brands Healthcare |
March 2009 | £8000 | 7.35 % |
|
The OTC market in Poland |
June 2006 | £1350 | 7.35 % |
|
Cosmetic Surgery Procedures and Products A US and European Market Review |
November 2009 | £2195 | 7.35 % |
|
Lung Cancer Therapeutics |
July 2009 | £2515 | 7.35 % |
|
Incremental Improvements And Paradigm Shifts In Strategy Are Both Necessary To Boost Productivity R&D Strategies |
August 2007 | £7600 | 7 % |
|
Pediatric Health Care Products and Services |
March 2009 | £3085 | 7 % |
|
Fresenius Medical Device Company Intelligence Report |
March 2009 | £295 | 7 % |
|
Chinese Markets for Health Care |
November 2006 | £2545 | 7 % |
|
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
November 2006 | £6000 | 7 % |
|
Rimonabant: The first of the Cannabinoid blockbusters |
June 2007 | £1499 | 7 % |
|
Pharmaceutical Outsourcing Opportunities Post-Launch Contract Manufacturing and Contract Sales and Marketing, 3rd Edition |
January 2009 | £2230 | 7 % |
|
The Top 100 Molecular Diagnostics Manufacturing Companies Worldwide |
March 2009 | £605 | 7 % |
|
Nanomaterials Markets by Type |
December 2005 | £3085 | 6.65 % |
|
RNAi Technologies, Markets and Companies |
February 2010 | £2230 | 6.65 % |
|
Antiviral Therapeutics Technologies, Markets and Companies |
February 2010 | £2035 | 6.65 % |
|
Growth Factors (Blood and Tissue) A World Report |
November 2009 | £1905 | 6.65 % |
|
The Royalty Rate Report 2009 A Comprehensive Assessment of Valuation in the Pharmaceutical Sector |
November 2008 | £3594 | 6.65 % |
|
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit |
July 2007 | £6000 | 6.65 % |
|
The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012 |
February 2007 | £1499 | 6.3 % |
|
Protein Therapeutics Market; The The Science and Business of a Growing Sector |
June 2006 | £2480 | 6.3 % |
|
Global Vaccines Market 2008-2023, The |
August 2008 | £1499 | 6.3 % |
|
New Dynamics and Challenges in The Generics Market 2007 |
January 2007 | £1870 | 5.95 % |
|
Infection Prevention Products & Services |
August 2009 | £2990 | 5.95 % |
|
Leading Pharmaceutical Companies Financial Analyses |
September 2009 | £1180 | 5.95 % |
|
Nanobiotechnology Applications, Markets and Companies |
February 2010 | £2865 | 5.95 % |
|
Antiageing and Life Enhancement Pharmacotherapeutics |
January 2006 | £795 | 5.6 % |
|
Outsourcing in Drug Discovery, 3rd Edition |
May 2008 | £1905 | 5.6 % |
|
Antibiotics and Drug Resistance 2008 Drug Innovation and the Strategy to Combat - Antibiotic Resistance Mechanisms |
January 2008 | £1499 | 5.6 % |
|
United States Drug Delivery Devices Medical Equipment Industry Report Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Infusion Systems, Inhalation Systems and Needle Free Injections Medical Equipment and Supplies |
April 2008 | £1910 | 5.25 % |
|
Autoimmune Disease Therapeutics |
July 2009 | £2515 | 5.25 % |
|
Dietary supplements market in Poland 2009 Development forecasts 2009-2011 |
March 2009 | £1310 | 4.9 % |
|
Nanomedicine |
July 2009 | £2515 | 4.9 % |
|
Pipeline and Commercial Insight: Nicotine Dependence - Chantix issues overshadow vaccine potential Healthcare |
March 2009 | £8000 | 4.55 % |
|
Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
April 2008 | £6000 | 4.2 % |
|
Injectable Generic Drugs Prospects & Opportunities to 2013 |
July 2008 | £1295 | 3.85 % |
|
Disposable Medical Supplies US industry forecasts for 2013 & 2018 |
July 2009 | £3055 | 3.85 % |
|
Pipeline/Commercial Insight: Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications |
June 2007 | £7600 | 2.8 % |
|
Pipeline Insight: Molecular Targeted Cancer Therapies More pipeline activity, less product differentiation |
November 2008 | £8000 | 2.45 % |
